Annexin A1 expression in a pooled breast cancer series : association with tumor subtypes and prognosis

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/164124

Lähdeviite

Sobral-Leite , M , Wesseling , J , Smit , V T H B M , Nevanlinna , H , van Miltenburg , M H , Sanders , J , Hofland , I , Blows , F M , Coulson , P , Patrycja , G , Schellens , J H M , Fagerholm , R , Heikkila , P , Aittomaki , K , Blomqvist , C , Provenzano , E , Ali , H R , Figueroa , J , Sherman , M , Lissowska , J , Mannermaa , A , Kataja , V , Kosma , V-M , Hartikainen , J M , Phillips , K-A , Couch , F J , Olson , J E , Vachon , C , Visscher , D , Brenner , H , Butterbach , K , Arndt , V , Holleczek , B , Hooning , M J , Hollestelle , A , Martens , J W M , van Deurzen , C H M , van de Water , B , Broeks , A , Chang-Claude , J , Chenevix-Trench , G , Easton , D F , Pharoah , P D P , Garcia-Closas , M , de Graauw , M , Schmidt , M K & kConFab-AOCS Investigators 2015 , ' Annexin A1 expression in a pooled breast cancer series : association with tumor subtypes and prognosis ' , BMC Medicine , vol. 13 , 156 . https://doi.org/10.1186/s12916-015-0392-6

Julkaisun nimi: Annexin A1 expression in a pooled breast cancer series : association with tumor subtypes and prognosis
Tekijä: Sobral-Leite, Marcelo; Wesseling, Jelle; Smit, Vincent T. H. B. M.; Nevanlinna, Heli; van Miltenburg, Martine H.; Sanders, Joyce; Hofland, Ingrid; Blows, Fiona M.; Coulson, Penny; Patrycja, Gazinska; Schellens, Jan H. M.; Fagerholm, Rainer; Heikkila, Paivi; Aittomaki, Kristiina; Blomqvist, Carl; Provenzano, Elena; Ali, Hamid Raza; Figueroa, Jonine; Sherman, Mark; Lissowska, Jolanta; Mannermaa, Arto; Kataja, Vesa; Kosma, Veli-Matti; Hartikainen, Jaana M.; Phillips, Kelly-Anne; Couch, Fergus J.; Olson, Janet E.; Vachon, Celine; Visscher, Daniel; Brenner, Hermann; Butterbach, Katja; Arndt, Volker; Holleczek, Bernd; Hooning, Maartje J.; Hollestelle, Antoinette; Martens, John W. M.; van Deurzen, Carolien H. M.; van de Water, Bob; Broeks, Annegien; Chang-Claude, Jenny; Chenevix-Trench, Georgia; Easton, Douglas F.; Pharoah, Paul D. P.; Garcia-Closas, Montserrat; de Graauw, Marjo; Schmidt, Marjanka K.; kConFab-AOCS Investigators
Tekijän organisaatio: Department of Obstetrics and Gynecology
Clinicum
Department of Pathology
Medicum
Kristiina Aittomäki / Principal Investigator
Department of Medical and Clinical Genetics
Department of Oncology
Päiväys: 2015-07-02
Kieli: eng
Sivumäärä: 11
Kuuluu julkaisusarjaan: BMC Medicine
ISSN: 1741-7015
DOI-tunniste: https://doi.org/10.1186/s12916-015-0392-6
URI: http://hdl.handle.net/10138/164124
Tiivistelmä: Background: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients. Methods: Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model. Results: The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05-1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91-1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17-2.45). Conclusions: ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.
Avainsanat: Breast cancer
Annexin A1
BRCA1 and BRCA2 mutations
GROWTH-FACTOR
PROTEIN-KINASE
CELLS
PHOSPHORYLATION
CHEMOTHERAPY
METASTASIS
SURVIVAL
COMPLEX
DIFFERENTIATION
ADENOCARCINOMA
3122 Cancers
3123 Gynaecology and paediatrics
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
s12916_015_0392_6.pdf 1.827MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot